-
Recent Posts
- Dementia-Friendly Communities Provision, Viewed as a Social Determinant of Health (JGCR / NHS England / WHO)
- International Perspectives on the Possible Impact of the COVID-19 Pandemic and Lockdown on Abuse of the Elderly (JGCR / American Journal of Geriatric Psychiatry / JAGS)
- Updates Relating to the Lancet Commission on Dementia Prevention, Intervention, and Care (Lancet / Alzheimer’s Research and Therapy / Alzheimer’s and Dementia)
- A Brief Review of How the COVID-19 Pandemic Relates to Elderly Care and Research (JGCR)
- Some Speculated / Potential Benefits of COVID-19 (JGCR / BBC Radio 4’s Rethink / BGS)
Archives
- September 2020
- August 2020
- June 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
Categories
- Antipsychotics
- Assistive Technology
- Charitable Bodies
- Commissioning
- Delirium
- Depression
- Enhancing the Healing Environment
- Falls
- Falls Prevention
- Guidelines
- Hip Fractures
- Housing
- Hypertension
- In the News
- Integrated Care
- International
- Local Interest
- Mental Health
- Models of Dementia Care
- National
- ADASS
- All-Party Parliamentary Group (APPG) on Dementia
- BSI
- CQC: Care Quality Commission
- Department of Health
- Department of Health and Social Care (DHSC)
- Health Education England (HEE)
- Housing LIN
- MAGDR
- Mental Health Foundation
- Mental Health Network (NHS Confederation)
- MHP Health Mandate
- National Audit Office
- National Voices
- NEoLCIN
- NEoLCP
- NHS
- NHS Alliance
- NHS Confederation
- NHS Employers
- NHS England
- NHS Evidence
- NHS Improvement
- NICE Guidelines
- NIHR
- NIHRSDO
- Northern Ireland
- Patients Association
- Public Health England
- RCN
- Royal College of Physicians
- Royal College of Psychiatrists
- SCIE
- Scotland
- UK
- UK NSC
- Wales
- Non-Pharmacological Treatments
- Nutrition
- Pain
- Parkinson's Disease
- Patient Care Pathway
- Person-Centred Care
- Personalisation
- Pharmacological Treatments
- Proposed for Next Newsletter
- Quick Insights
- Standards
- Statistics
- Stroke
- Systematic Reviews
- Telecare
- Telehealth
- Universal Interest
Google Translate (100+ Languages)
Tag Archives: Dementia Research Funding
Dementia Moonshot Report: Research Priorities and Costs (Alzheimer’s Research UK)
Summary Alzheimer’s Research UK (ARUK) have released a brief report on six research priorities, which are: Achieving earlier detection of diseases which may cause dementia, (ideally by 10-15 years), to enhance development of new treatments / interventions for people most … Continue reading →
Posted in Alzheimer’s Research UK, Charitable Bodies, Commissioning, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, Models of Dementia Care, National, Non-Pharmacological Treatments, Pharmacological Treatments, Quick Insights, UK, Universal Interest
|
Tagged Accelerating Alzheimer's Research and Drug Development, Accelerating Detection of Disease, Accelerating Detection of Disease (ADD) Challenge, Accelerating Detection of Disease Programme, Alzheimer's and Dementia: Translational Research and Clinical Interventions (TRCI), Alzheimer’s Research UK (ARUK), Alzheimer’s Research UK’s Dementia Attitudes Monitor, Alzheimer’s Research UK’s Drug Discovery Alliance, Awareness, Awareness Raising, Benefits of Detection and Early Intervention, Benefits of Early Detection, Biomarker Development, Biomarkers, Brain Health Clinics, Charity Research Support Fund, Cognitive Function and Ageing Study II, Cross-Funder Review, Dementia Access Taskforce, Dementia Consortium, Dementia Moonshot, Dementia Prevalence, Dementia Prevention, Dementia Research, Dementia Research and Drug Development, Dementia Research Funding, Dementia Research Priorities, Dementia Risk Reduction, Dementia Risk Reduction and Prevention, Dementia Translational Medicines Accelerator, Dementia: Prevalence and Detection, Dementias Platform UK, DPUK: Dementias Platform UK, Dr Helen Beaumont: Alzheimer’s Research UK Champion, Drug Development for Alzheimer's Disease, Drug Discovery Alliance, Drug Discovery Institutes, Drug Target Validation, Early Detection of Neurodegenerative Diseases, Economic Impact of Dementia, Global Impact of Dementia, Global Leadership, Government Research Funding, Grand Challenge on Artificial Intelligence and Data, Helen Stokes-Lampard: Chair of RCGP, Hilary Evans: Chief Executive of Alzheimer’s Research UK, Impact of Dementia, Impact of Dementia (Statistics), Impact of Dementia in UK, Life Sciences Industrial Strategy, Life-Changing Treatment for Dementia by 2025 (Moonshot Aim), Medical Research Charities, Mike Gooley Trailfinders Charity Prevention and Risk Reduction Fund, Modifiable Risk Factors, Multi-Morbidities, Multi-Morbidity, No Time to Lose: An Action Plan for Dementia (ARUK), Participation in Research, Patient Involvement in Research, Potential Drug Targets, Preclinical Biomarkers and Dementia, Preclinical Biomarkers in Alzheimer's Disease, Professor Jamie Waterall: National Lead for Cardiovascular Disease at Public Health England, Professor Tara Spires-Jones: Alzheimer’s Research UK Grant Review Board, Research Funding, Research Priorities and Funding / Costs, Research Priorities and Networks, Social and Economic Impact of Dementia, Social and Economic Impact of Dementia in UK, Target Robustness Programme, Translational Medicines, Translational Research, UK Dementia Research Institute, UK Dementia Research Institute (UK DRI), UK Health Research Funding
|
Leave a comment
The State of Dementia Research Globally: World Alzheimer Report 2018 (Alzheimer’s Disease International)
Summary The World Alzheimer Report 2018, entitled “The state of the art of dementia research: New frontiers”, reviews developments in dementia research, without glossing-over the absence of significant disease-modifying pharmacological treatment breakthroughs for around 20 years. This report examines wide-ranging … Continue reading →
Posted in Acute Hospitals, Alzheimer’s Disease International (ADI), Charitable Bodies, Community Care, Diagnosis, For Carers (mostly), For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), International, Management of Condition, Mental Health, Models of Dementia Care, Person-Centred Care, Quick Insights, Standards, Statistics, UK, Universal Interest
|
Tagged ADI’s World Alzheimer Reports, Alireza Atri: Director of Banner Sun Health Research Institute, Alzheimer's Research, Alzheimer’s Disease International (ADI), Alzheimer’s Disease Research Unit: McGill Centre for Studies in Ageing (Canada), Alzheimer’s Prevention Initiative: Banner Health (USA), Alzheimer’s Prevention Initiative: Banner Sun Health Research Institute, Banner Sun Health Research Institute, Burden of Alzheimer’s Disease, Burden of Dementia (Statistics), Centre for Dementia Prevention: University of Edinburgh, Dementia as Cause of Death, Dementia Awareness, Dementia Awareness Raising, Dementia Collaborative Research Centre: University of New South Wales, Dementia Discovery Fund, Dementia Discovery Fund (DDF), Dementia Prevention, Dementia Research, Dementia Research Funding, Dementia Research Priorities, Dementia Risk Reduction, Dementia Risk Reduction and Prevention, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies for Dementia, Disease-Modifying Treatments for Dementia, Dr Christopher Chen: Director of Memory Ageing and Cognition Centre at National University Health System: Singapore, Dr Doug Brown: Chief Executive Officer of British Society for Immunology, Dr Doug Brown: Former Chief Policy and Research Officer at Alzheimer’s Society, Dr Jennifer Bute: Dementia Alliance International (DAI), Dr Kenji Toba: President of National Centre for Geriatrics and Gerontology (Obu), Dr Maria Carrillo: Chief Science Officer at Alzheimer’s Association US, Dr Miia Kivipelto: Karolinska Institute, Dr Miia Kivipelto: Karolinska University Hospital (Stockholm), Dr Rachelle Doody: Global Head of Neurodegeneration at Roche, Dr Serge Gauthier: Director of Alzheimer’s Disease Research Unit at McGill Centre for Studies in Ageing in Canada, Drug Trials Failure Rate, Epidemiology, Epidemiology and Statistics, Francesca Colombo: Organisation for Economic Co-operation and Development (OECD), Fundación para la Lucha contra las Enfermedades Neurológicas (FLENI), Glenn Rees: Chairman of Alzheimer’s Disease International, Glenn Rees: Former CEO of Alzheimer’s Australia, Global Burden of Dementia, Global Dementia Discovery Fund (2015), Identification and Intervention for Dementia in Elderly Africans (IDEA Group), Jeff Cummings: Director of Cleveland Clinic at Lou Ruvo Centre for Brain Health, Kate Bingham: SV Health Managers, King’s College London, Market Failure (Dementia Research and Drug Development), Martin Knapp: London School of Economics, Memory Ageing and Cognition Centre at National University Health System: Singapore, Memory Ageing and Cognition Centre: National University Health System (Singapore), National Centre for Geriatrics and Gerontology (Japan), Optima (University of Oxford’s Dementia Research Project), OPTIMA Cohort (Oxford Project to Investigate Memory and Ageing), Oxford Project to Investigate Memory and Ageing (OPTIMA Study), Paola Barbarino: Alzheimer’s Disease International, Prevention, Prevention Agenda, Prevention of Future Dementia Cases by Increasing Knowledge of Risk and Protective Factors, Professor Adesola Ogunniyi: University College Hospital (Ibadan), Professor Bart De Strooper: Director of the UK Dementia Research Institute (UK DRI), Professor Craig Ritchie: Chair of Psychiatry of Ageing at University of Edinburgh, Professor Craig Ritchie: Director at Centre for Dementia Prevention, Professor Gordon Wilcock: Co-founder of Alzheimer’s Society UK, Professor Gordon Wilcock: Emeritus Professor of Geratology at University of Oxford, Professor Henry Brodaty: Director of Dementia Collaborative Research Centre at University of New South Wales, Professor Martin Knapp: Director of the Personal Social Services Research Unit at the London School of Economics and Political Science (LSE), Professor Martin Prince: Assistant Principal for Global Health at King’s College London, Research Networks, Ricardo Allegri: Head of Cognitive Neurology Neuropsychology and Neuropsychiatry at Fundación para la Lucha contra las Enfermedades Neurológicas (FLENI), Risk and Protective Factors, State of the Art of Dementia Research: New Frontiers (World Alzheimer Report 2018), Supporting People Affected by Dementia, UK Dementia Research Institute, UK Dementia Research Institute (UK DRI), UK Dementia Research Institute at UCL, University College Hospital (Ibadan Nigeria), World Alzheimer Report, World Alzheimer Report 2018: State of the Art of Dementia Research, World Alzheimer Report: 2018, World Alzheimer’s Day 2018
|
Leave a comment
Plans for Meeting the Dementia Challenge by 2020 (DHSC)
Summary The Prime Minister’s Challenge on Dementia 2020 (2015) involved over 50 commitments for making England the best place in the world for dementia care, research and public dementia awareness in general. Feedback was subsequently collected, during 2018, concerning developments … Continue reading →
Posted in Acute Hospitals, Charitable Bodies, Commissioning, Community Care, Department of Health, Department of Health and Social Care (DHSC), Diagnosis, End of Life Care, For Carers (mostly), For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), For Social Workers (mostly), Integrated Care, Management of Condition, Models of Dementia Care, National, NHS, Non-Pharmacological Treatments, Person-Centred Care, Personalisation, Quick Insights, Standards, UK, Universal Interest
|
Tagged Achieving Dementia Friendly Acute care, Ageing and Dementia, Ageing and Society, Ageing Policy in the UK, Ageing Population, Alzheimer's Association, Alzheimer’s Research UK (ARUK), Alzheimer’s Society Connecting Communities Project, Awareness and Understanding, Awareness Campaigns, Behavioural Risk Factors, Behavioural Risk Factors and Dementia, Black Asian and Minority Ethnic (BAME), Black Asian and Minority Ethnic Communities (UK), Building Dementia Friendly Communities, Burden of Dementia, Care and Compassion, Care at Home, Care Plan Template for Dementia, Carer Support, Carer Support Services, Challenge by 2020: National Partners and Stakeholders, Challenge on Dementia 2020, Challenge on Dementia 2020 Implementation Plan, Citizen Participation, Civil Service Learning, Collaboration, Collaborative Projects, Collaborative Research, Collaborative Working, Commitment to Carers (NHS England), Community Participation, Compassionate Care, Connecting Communities, Connecting Communities Initiative, Creating Dementia Friendly Environments, Creating Dementia Friendly Hospitals, Cross-Sector Partnerships, Dementia 2020 Challenge: 2018 Review Phase 1 (DHSC), Dementia 2020 Challenge: 2019 Progress Review - Phase 1 (2019), Dementia 2020 Citizens’ Panel, Dementia Action Alliance (DAA), Dementia Advisers, Dementia Advisor, Dementia Advisor Service, Dementia Awareness, Dementia Awareness and Social Action, Dementia Awareness Training, Dementia Challenge, Dementia Consortium, Dementia Core Skills Education and Training Framework, Dementia Data and Metrics, Dementia Friendly Charters, Dementia Friends, Dementia Friends Campaign, Dementia Friends Champions, Dementia Friends Programme, Dementia Health and Care Champion Group, Dementia Intelligence Network (DIN), Dementia Metrics, Dementia Research, Dementia Research Funding, Dementia Research Institute, Dementia Research Roadmap for Prevention Diagnosis Intervention and Care by 2025 (Alzheimer’s Society), Dementia Risk Factors, Dementia Risk Reduction, Dementia Risk Reduction and Prevention, Dementia State of the Nation, Dementia Treatment and Care Pathway, Dementia UK, Dementia-Friendly Businesses, Dementia-Friendly Care Homes, Dementia-Friendly Cities, Dementia-Friendly Communities, Dementia-Friendly Employers, Dementia-Friendly Hospitals, Dementia-Friendly Housing, Dementia-Friendly Neighbourhoods, Dementia-Friendly Sectors, Dementia-Friendly Towns, Department of Health Dementia Challenge, Department of Health Dementia Challenge (2020), Diagnosis and Referral, Dignity in Dementia, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Global Leadership, Global Outlook, Government Research Funding, GPs Taking Leading Role, Healthy Behaviours, Healthy Communities, Healthy Lifestyles, Improving Care for People with Dementia, Inappropriate Prescribing, Inappropriate Use of Antipsychotics in Dementia, Information and Metrics, Integration of Health and Care, International Collaborations, International Dementia Research Inventories, International Framework for Dementia Research, International Programmes, Involvement and Participation, Join Dementia Research, Lifestyle Risk Factors, Local Dementia Action Alliances, Meaningful Care, National Audit of Dementia (Care in General Hospitals), National Audit of Dementia (NAD), National Audit of Dementia Care in General Hospitals 2016-2017 - Third Round of Audit Report: Royal College of Psychiatrists (2017), NHS Health Check, NHS Health Check Programme, Non-Treatment Research, One You Campaign (PHE), Participation in Research, Partnership and Collaboration, Partnership Working, Patient and Public Participation, Referrals, Regional Targets (Metrics), Research and Innovation, Research Funding, Risk Factors, Risk Factors for Alzheimer's Diseease, Risk Management, Royal College of Psychiatrists: National Audit of Dementia Care in General Hospitals, Skills for Care (SfC), Social Care Institute for Excellence (SCIE), Support for Carers, Sustainable Care, Unhealthy Lifestyles, Well Pathway for Dementia
|
Leave a comment
Dementia Researchers Recognised and Rewarded (BBC News / Lundbeck Foundation)
Summary Four dementia researchers share the 2018 (€1 million Euro) Brain Prize (bestowed by the Lundbeck Foundation), in recognition of their joint work on the underlying neuropathological mechanisms thought to cause of Alzheimer’s Disease. Full Text Link Reference Roberts, M. … Continue reading →
Posted in BBC News, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, Quick Insights, UK, Universal Interest
|
Tagged Abnormal Proteins, Abnormal Proteins (Tau), Alzheimer’s Disease, Alzheimer’s Disease and Dementia, Alzheimer’s Disease: Causes, Amyloid Beta Protein, Amyloid Cascade Hypothesis, Amyloid Proteins, Amyloid-β Protein, Annual €1 Million Brain Prize, Apolipoprotein E (APOE) Gene, Asymptomatic Alzheimer’s Disease, Cambridge University, Dementia Research, Dementia Research Careers, Dementia Research Funding, Genetic Research, Germany, Global Context, Global Dementia Research, Global Outlook, β-Amyloid Precursor Protein (APP), Lundbeck Foundation (Denmark), Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neurodegenerative Disorders, Neuropathologic Disorders, Neuropathology, Pathophysiological Processes in Alzheimer’s Disease, Professor Bart De Strooper: Director of the UK Dementia Research Institute (UK DRI), Professor Christian Haass, Professor John Hardy, Professor Michael Goedert, The Brain Prize (Lundbeck Foundation), UK Dementia Research Institute, UK Dementia Research Institute (UK DRI), UK Dementia Research Institute at UCL, University College London, University of Munich
|
Leave a comment
A Further Set-Back for Progress in Dementia Drug Development? (BBC News)
Summary Drug company Pfizer is to cease activity in its neuroscience drug discovery programmes, which will impact on ongoing research into drugs for Alzheimer’s Disease and Parkinson’s Disease. Paradoxically the company does promise plans to create a new fund dedicated … Continue reading →
Posted in BBC News, For Researchers (mostly), In the News, International, Management of Condition, Pharmacological Treatments, Quick Insights, Universal Interest
|
Tagged Big Pharma, Dementia Research, Dementia Research Funding, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Drug Discovery Programmes, Drug Identification, Drug Trials Failure Rate, Drug-Development Pipeline, Global Context, Global Outlook, International Organisations, International Programmes, Neurological Conditions, Neurological Disease, Neurological Disorders, Neuroscience Drug Discovery Programmes (Pfizer), Neuroscience Research, Pfizer, Pfizer Inc., Pharmaceutical Industry, Research and Development, Research and Innovation, Research Commitment, Research Funding
|
Leave a comment
Earlier Diagnosis Research: the Deep and Frequent Phenotyping Study (BBC News / GtR)
Summary The Deep and Frequent Phenotyping Study aims to discover new ways of diagnosing dementia, ideally decades before the symptoms become apparent in order to give future drug treatments the best chance of working. The Deep and Frequent Phenotyping Study … Continue reading →
Posted in Alzheimer's Society, BBC News, Commissioning, Diagnosis, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, Mental Health, Models of Dementia Care, National, NIHR, Quick Insights, UK, Universal Interest
|
Tagged Ageing Population, Alterations in Movement and Walking (“Gait”) Assessments, Alzheimer's Disease: Early Detection by Brain Scan, Alzheimer’s Disease Biomarkers, Amnestic Mild Cognitive Impairment (a-MCI), Amnestic Mild Cognitive Impairment (aMCI), Applications of Big Data, BBC Radio, BBC Radio 4, BBC's World At One Programme, Big Data Analytics, Big Data Funding and Research, Biomarker Assessments in Alzheimer’s Disease, Biomarker Assessments in Alzheimer’s Disease Clinical Trials, Biomarker Assessments in Clinical Trials, Biomarker Development, Biomarkers, Biomarkers Predicting Cognitive Decline and Alzheimer's Disease, Biomarkers Research Programmes, Blood and Urine Biomarkers, Blood-Based Biomarkers, Blood-Based Biomarkers of Pre-Symptomatic Alzheimer’s Disease, Brain Scans, Cambridge Neuropsychological Test Automated Battery (CANTAB), Cerebrospinal Fluid (CSF) Biomarkers, Clinical Assessments, Cognitive Assessments / Screening Tools, Conversion to Dementia From Prodromal Disease, CSF Biomarkers, Deep and Frequent Phenotyping Study, Deep and Frequent Phenotyping Study (DFP), Deep and Frequent Phenotyping; Combinatorial Biomarkers of Dementia, Dementia Research, Dementia Research Funding, Dementias Platform UK, Dementias Platform UK (DPUK), Dementias Platform UK: MRC, DFP Study Team, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, DPUK: Dementias Platform UK, Drug Trials Failure Rate, Early Detection of Alzheimer’s Disease, Early Detection of Preclinical Disease, EEG: Electroencephalography, Effectiveness of Early Detection and Treatment, Electroencephalogram (EEG) Brain Scans, Electroencephalography (EEG), Gait and Cognition, Gait Changes, Gateway to Research (GtR), Global Dementia Research, Global Leadership, Hypothetical Prodromes of Dementia, Imanova, Imperial College London, Join Dementia Research, Join Dementia Research: Clinical Trials Matchmaker Service, Join Dementia Research: Recruitment Onto Dementia Studies, Kings College London, Magnetic Resonance Imaging (MRI) Scan, Magnetoencephalography (MEG), Medical Research Council (MRC), Medical Research Council (UK), National Institute of Health Research (NIHR), Neurobiology of Aging (Journal), Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neurodegenerative Disorders, Neurodegenerative Research, Newcastle University, Non-Invasive Biomarkers, Ocular Manifestations in Neurodegenerative Diseases, Open Data and Big Data, Ophthalmological Assessments, Participation in Research, Participation in Research Studies, Partnership and Collaboration, Patient and Public Participation, PharmaCog Consortium, Positron Emission Tomography (PET), Pre-Clinical Genotype-Phenotype Predictors of Alzheimer's Disease, Prodromal Alzheimer's Disease, Professor Clare Mackay: Imaging Neuroscience at the University of Oxford, Professor Lynn Rochester: Clinical Ageing Research Unit at Newcastle University, Professor Simon Lovestone: Lead Researcher and Professor of Translational Neuroscience at University of Oxford, Protein-Based Biomarkers in Blood May Deliver Accurate Diagnoses, Proteomic Analysis, Proteomics, Public Participation in Research, Publicly-Funded UK Big Data Research, Research and Development, Research and Innovation, Research Commitment, Research Culture, Research Funding, Retina as Early Biomarker of Neurodegeneration, Retinal Biomarkers, Retinal Changes as Surrogate Biomarker for Alzheimer's Disease, Retinal Ganglion Cells (RGCs), Retinal Manifestations of Alzheimer's Disease, Screening Tools for Amnestic Mild Cognitive Impairment (a-MCI), Surrogate Biomarkers of Neurodegeneration, Translational Research, University College London, University of Cambridge, University of Edinburgh, University of Manchester, University of Oxford, Volunteers, Walking Pattern (Gait), Wearable Devices, Wearables (Technology)
|
Leave a comment
David Cameron on Need for Increasing Dementia Research Funding (BBC News)
Summary David Cameron, the former Prime Minister, has taken-up the role of President of Alzheimer’s Research UK (in addition to working for the National Citizen Service). He has proposed / re-stated the importance of greater levels of funding for dementia … Continue reading →
Posted in Alzheimer’s Research UK, BBC News, Commissioning, In the News, Management of Condition, Mental Health, National, Non-Pharmacological Treatments, Person-Centred Care, Quick Insights, UK, Universal Interest
|
Tagged Alzheimer's Research UK, Alzheimer’s Research UK (ARUK), ARUK: Alzheimer’s Research UK, BBC Health News, BBC Politics News, Challenge on Dementia (David Cameron), Challenge on Dementia 2020, David Cameron, David Cameron: Former Prime Minister, David Cameron: President of Alzheimer's Research UK, Defeat Dementia Campaign, Defeat Dementia Campaign (Alzheimer’s Research UK), Dementia Awareness, Dementia Awareness Raising, Dementia Research, Dementia Research Funding, Dementia Risk Prevention, Dementia Risk Reduction and Prevention, Dementia-Friendly Communities, Dementia-Friendly Environments, Investment in Dementia Prevention, National Citizen Service, National Citizen Service in England and Northern Ireland, Prevention Agenda, Prime Minister's Challenge on Dementia, Prime Minister’s Challenge On Dementia 2020, The Rt Hon David Cameron: President of Alzheimer’s Research UK
|
Leave a comment
Deep and Frequent Phenotyping Study: Dementia Early Detection and Biomarkers Research Programme (MRC / NIHR)
Summary The Deep and Frequent Phenotyping Study will explore improvements in biomarker research and the development of tests to detect Alzheimer’s Disease early on. This research programme will be funded by the National Institute of Health Research (NIHR) and the … Continue reading →
Posted in Alzheimer's Society, Charitable Bodies, Commissioning, Diagnosis, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, National, NIHR, Quick Insights, UK, Universal Interest
|
Tagged Alterations in Movement and Walking (“Gait”) Assessments, Alzheimer's Disease: Early Detection by Brain Scan, Alzheimer’s Disease Biomarkers, Aridhia, AstraZeneca / MedImmune, Berry Consultants, Biomarker Assessments in Alzheimer’s Disease, Biomarker Assessments in Alzheimer’s Disease Clinical Trials, Biomarker Assessments in Clinical Trials, Biomarker Development, Biomarkers, Biomarkers Predicting Cognitive Decline and Alzheimer's Disease, Biomarkers Research Programmes, Blood and Urine Biomarkers, Blood-Based Biomarkers, Blood-Based Biomarkers of Pre-Symptomatic Alzheimer’s Disease, Brain Scans, Cambridge Cognition, Cerebrospinal Fluid (CSF) Biomarkers, Clinical Assessments, Cognitive Assessments / Screening Tools, Conversion to Dementia From Prodromal Disease, CSF Biomarkers, Deep and Frequent Phenotyping Study, Dementia Research, Dementia Research Funding, Dementias Platform UK, Dementias Platform UK (DPUK), Dementias Platform UK: MRC, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, DPUK: Dementias Platform UK, Dr Rob Buckle: Director of Science Programmes at MRC, Drug Trials Failure Rate, Early Detection of Alzheimer’s Disease, Early Detection of Preclinical Disease, EEG: Electroencephalography, Effectiveness of Early Detection and Treatment, Electroencephalogram (EEG) Brain Scans, Electroencephalography (EEG), Exprodo, Gait and Cognition, Gait Changes, Global Dementia Research, Global Leadership, Hypothetical Prodromes of Dementia, Imanova, Imperial College London, IXICO, Kings College London, Magnetic Resonance Imaging (MRI) Scan, Magnetoencephalography (MEG), Medical Research Council (MRC), Medical Research Council (UK), National Institute of Health Research (NIHR), Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neurodegenerative Disorders, Neurodegenerative Research, Newcastle University, Non-Invasive Biomarkers, Ocular Manifestations in Neurodegenerative Diseases, Ophthalmological Assessments, Optos, Participation in Research, Participation in Research Studies, Partnership and Collaboration, Patient and Public Participation, Positron Emission Tomography (PET), Pre-Clinical Genotype-Phenotype Predictors of Alzheimer's Disease, Prodromal Alzheimer's Disease, Professor Chris Whitty: Chief Scientific Adviser at Department of Health, Professor Simon Lovestone: Lead Researcher and Professor of Translational Neuroscience at University of Oxford, Protein-Based Biomarkers in Blood May Deliver Accurate Diagnoses, Proteomic Analysis, Proteomics, Public Participation in Research, Research and Development, Research and Innovation, Research Commitment, Research Culture, Research Funding, Retina as Early Biomarker of Neurodegeneration, Retinal Biomarkers, Retinal Changes as Surrogate Biomarker for Alzheimer's Disease, Retinal Ganglion Cells (RGCs), Retinal Manifestations of Alzheimer's Disease, Sage Bionetworks, Surrogate Biomarkers of Neurodegeneration, Translational Research, TrialSpark, University College London, University of Cambridge, University of Edinburgh, University of Manchester, University of Oxford, Volunteers, Walking Pattern (Gait), Wearable Devices, Wearables (Technology), West London Mental Health Trust / Imperial College London
|
1 Comment
Timely Reflections on Dementia Awareness (NHS England / UKMi)
Summary Professor Alistair Burns, NHS England’s National Clinical Director for Dementia, marks National Dementia Awareness Week. Full Text Link Reference Great strides are being made in dementia awareness – Professor Alistair Burns. London: NHS England, May 20th 2016. Further elaboration, … Continue reading →
Posted in Alzheimer's Society, Diagnosis, For Carers (mostly), For Nurses and Therapists (mostly), For Social Workers (mostly), In the News, Integrated Care, Management of Condition, Mental Health, Models of Dementia Care, National, NHS, NHS England, Non-Pharmacological Treatments, Patient Care Pathway, Patient Information, Person-Centred Care, Personalisation, Pharmacological Treatments, Quick Insights, UK, Universal Interest
|
Tagged Ageing and Dementia, Ageing and Society, Alistair Burns, Alistair Burns: Honorary Consultant Old Age Psychiatrist in the Manchester Mental Health and Social Care Trust (MMHSCT), Alistair Burns: NHS England’s National Clinical Director for Dementia, Alistair Burns: Professor of Old Age Psychiatry at University of Manchester, Awareness and Understanding, Awareness Campaigns, Barriers to Early Diagnosis, Care Planning, Delays in Diagnosis of Dementia, Dementia Awareness Week, Dementia Awareness Week (2016), Dementia Diagnosis, Dementia Diagnosis and Care in England, Dementia Diagnosis Rates, Dementia Friends, Dementia Friends Programme, Dementia Research, Dementia Research Funding, Dementia-Friendly Communities, Diagnosis, Diagnosis and Assessment, Diagnosis of Dementia, Early Diagnosis, Living Well with Dementia, medeConnect, Myth-Busting, Myths and Misconceptions About Dementia, National Dementia Awareness Week, National Dementia Helpline, Post-Diagnosis Support, Post-Diagnostic Dementia Support, Post-Diagnostic Support, Reasons For Delays in Diagnosis of Dementia, Reducing Stigma, Southampton Medicines Advice Service, Staying Healthy for Longer, Stigma-Free Environments, Thinking Ahead: Dementia Awareness Week (Theme Revamped For 2016), Timely Diagnosis, UK Medicines Information (UKMi), UKMi, YouGov Plc
|
Leave a comment
Further Funding for the Dementia Research Institute (Gov UK / MRC / Alzheimer’s Society / ARUK)
Summary Additional partnership funding has been announced for Dementia Research Institute (DRI). The Alzheimer’s Society and Alzheimer’s Research UK have each committed £50 million towards supporting the work of the Institute, making the total commitment to date around £250 million … Continue reading →
Posted in Alzheimer's Society, Alzheimer’s Research UK, Charitable Bodies, Commissioning, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, Mental Health, Models of Dementia Care, National, Non-Pharmacological Treatments, Pharmacological Treatments, Quick Insights, UK, Universal Interest
|
Tagged Alzheimer’s Research UK (ARUK), Alzheimer’s Research UK’s Drug Discovery Alliance, ARUK: Alzheimer’s Research UK, Challenge on Dementia (David Cameron), Challenge on Dementia 2020, Cross-Sector Partnerships, David Cameron, Dementia Research, Dementia Research Careers, Dementia Research Funding, Dementia Research Institute (DRI), Dementia Research: UK Impact, Dementia Risk Reduction, Department for Business Innovation and Skills, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Drug Discovery Alliance, Drug Discovery Programmes, Global Action Against Dementia, Global Context, Global Dementia Discovery Fund (2015), Global Dementia Research, Global Leadership, Global Outlook, Hilary Evans: Chief Executive of Alzheimer’s Research UK, International Dementia Research, Jeremy Hughes CBE: Chief Executive of the Alzheimer’s Society, Jo Johnson MP, Jo Johnson: Universities and Science Minister, Living Well with Dementia Research, Medical Research Council (MRC), Medical Research Council (UK), MRC: Medical Research Council, Neurodegeneration, Neurodegenerative Disease Research, Partnership and Collaboration, Partnership Working, Prime Minister’s Challenge On Dementia 2020, Promisary Science, Public Health Strategies, Research and Development, Research and Innovation, Research Commitment, Research Funding, Sir John Savill: Chief Executive of the Medical Research Council, UK Dementia Research Institute
|
Leave a comment
